FIGURE 2.
FIGURE 2.
Time curve of percentage of unchanged radioligand and metabolites in total plasma radioactivity using 11C-verapamil in 10 subjects.
In this issue
Related Articles
Cited By...
- Avoiding Barriers to PET Radioligand Development: Cellular Assays of Brain Efflux Transporters
- Lysosomal trapping of a radiolabeled substrate of P-glycoprotein as a mechanism for signal amplification in PET
- Imaging of Cyclosporine Inhibition of P-Glycoprotein Activity Using 11C-Verapamil in the Brain: Studies of Healthy Humans
- Human Brain Imaging and Radiation Dosimetry of 11C-N-Desmethyl-Loperamide, a PET Radiotracer to Measure the Function of P-Glycoprotein
- Tariquidar-Induced P-Glycoprotein Inhibition at the Rat Blood-Brain Barrier Studied with (R)-11C-Verapamil and PET
- Evaluation of In Vivo P-Glycoprotein Function at the Blood-Brain Barrier Among MDR1 Gene Polymorphisms by Using 11C-Verapamil